Evolving Treatment Landscape for PsA

Multiple Domains of PsA: A Challenge in Diagnosis

Treat-to-Target Recommendations

MDA Criteria

GRAPPA Treatment Schema for Active PsA

IL-17: Critical Role in the Pathogenesis of PsA and Psoriasis

Agents for the Treatment of PsA

Safety and Efficacy of IV Golimumab in Patients With Active PsA: GO-VIBRANT

Safety and Efficacy of Ustekinumab, an Anti-IL-12/23 p40 Monoclonal Antibody

IL-17 Isoforms, Their Receptors, and Key Molecules Involved in Signal Transduction

Bimekizumab: Dual IL-17A and IL-17F Inhibitor

IL-17 Inhibitors in PsA: ACR20 Response

Efficacy and Safety of IL-17 Inhibitors in Patients With Psoriasis

Concomitant Use of MTX With Biologic Therapy

IL-17A Inhibitors Prevent Radiographic Progression

Efficacy of Secukinumab in Patients With PsA: Results From FUTURE 5

Efficacy of Ixekizumab in Patients With PsA: Results From SPIRIT-P1

Safety Profile of IL-17 Inhibitors in PsA

Efficacy and Safety of Apremilast in Patients With PsA: Results From PALACE 1

Efficacy and Safety of Tofacitinib in Patients With PsA

Other Non-TNF Biologics in PsA: ACR20 Response

CVD in Patients With PsA

PsA Treatments and Their Effects on CV Outcomes

Weight Gain With Anti-TNF Agents

Depression in Patients With PsA

PsA: Choice of Therapy

Importance of Individualized Therapy for Patients With PsA

Holistic Approach to the Management of Patients With Psoriatic Disease

Abbreviations

Abbreviations (cont)

Abbreviations (cont)